Inhibikase Therapeutics, Inc.
- IKT
- NASDAQ
- Biotechnology
- Clinical-Stage Biopharma
- Pulmonary Arterial Hypertension (PAH)
$1.65
Today −9.84%Quote Oct 16, 2026, 08:00 PM UTC
−28.26%over the last month
Max drawdown −28.6%From 1-month high −28.6%3 months −26.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$230.2M
Quote Oct 16
Next earnings
Nov 13
Expected, not confirmed
Analyst target
$4.83
+192.7% from here
Floor
$1.61
2.3% below price
Where the price sits
2 analysts
Analyst range, low to high
$1.50$8.00
- Price $1.65
- Resistance $1.69
- Consensus $4.83
The price is right under resistance. Analysts' average target sits about 193% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IKTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
35
Founded
2008